Brief: SillaJen Submits CSR To US FDA For REN026 Study In Patients With RCC
27/03/2024 13:09
March 27 (Reuters) - SillaJen Inc 215600.KQ :
* SILLAJEN SUBMITS CSR TO THE US FDA FOR REN026 STUDY IN
PATIENTS
WITH RCC
Source text for Eikon: ID:nBw9cg5XFa
Further company coverage: 215600.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SillaJen
See all newsBrief: SillaJen Submits CSR To US FDA For REN026 Study In Patients With RCC
S.Korean stocks gain on improved sentiment in pharma sector
S.Korea stocks slump over 2% on escalating tension with Japan, trade worries
S.Korea's pharma firms plunge after SillaJen's halted clinical tests
Brief: Regeneron and Sillajen report immuno-oncology clinical study agreement